AREG exceeds AFP levels in sensitivity as a serum biomarker and is closely associated with YAP and TAZ activity, further emphasizing its diagnostic and therapeutic significance in HCC (Han et al., 2014[43]). The gene discussed is YAP1; the disease is hepatocellular carcinoma.